

November 27, 2019

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officer and Other Key Positions

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) today announced that the following organizational realignment and changes in Executive Officer and other key positions.

I. Organizational Realignment (effective December 1, 2019)

Corporate Departments

Global Data Design Office is created.

On October 31, 2019, Sumitomo Dainippon Pharma signed a definitive agreement for a Strategic Alliance with Roivant Sciences Ltd. and will acquire the basic technology and talent involved in Roivant's healthcare technology platform, DrugOme and Digital Innovation. Also under the plan is a business alliance that will allow Sumitomo Dainippon Pharma to utilize healthcare data connectivity technology owned by Datavant, Inc., one of Roivant's subsidiaries, focusing on healthcare information technology. In order to facilitate the utilization of these technologies throughout the Sumitomo Dainippon Pharma Group, a Global Data Design Office will be created. Through close cooperation with relevant organizations at a new U.S. subsidiary established for this Strategic Alliance, Sumitomo Dainippon Pharma will promote the use of DrugOme and Digital Innovation, in a bid to increase efficiency in the development of new medicines and promote digital transformation throughout the Group, inclusive of international subsidiaries.

Sales & Marketing (Division)

MarTech Strategy Office is created.

Now that businesses related to information technology and media at the Sales & Marketing Division have reached a stage where digital technologies leveraging AI and big data are ready to be applied extensively to day-to-day operations, such businesses shall be transferred from the Division's Sales & Marketing Management to a newly-created MarTech Strategy Office. The MarTech Strategy Office will be responsible for the promotion of digital transformation at the Division.

Created by combining the words "Marketing" and "Technology," MarTech refers to an approach by an enterprise to assimilate digital technologies into marketing activities for greater efficiency of their business.

II. Change in Executive Officer

Change in the position assumed by Executive Officer (effective December 1, 2019)

Position as of December 1, 2019	Current position	Name
Senior Executive Officer Global Corporate Strategy; Global Data Design Office; IT Management & Digital Transformation; Frontier Business Office	Senior Executive Officer Global Corporate Strategy; IT Management & Digital Transformation; Frontier Business Office	Hiroyuki Baba

III. Changes in Personnel (effective December 1, 2019)

Corporate Departments

Position as of December 1, 2019	Current position	Name
Senior Strategic Officer-Roivant Strategic Alliance	Director, Corporate Planning Group, Global Corporate Strategy	Yuichiro Haruyama
Senior Director, Global Data Design Office	Senior Director, Data Science	Satoru Tsuchiya

Drug Development (Division)

Position as of December 1, 2019	Current position	Name
Senior Director, Data Science Director, Biostatistics Group, Data Science	Director, Biostatistics Group, Data Science	Hisao Takeuchi

Sales & Marketing (Division)

Position as of December 1, 2019	Current position	Name
Senior Director, MarTech Strategy Office	Senior Digital Officer	Kyoichi Yokota

Contact:

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)